Nexcap (Nizatidine)

Adult dose

Treatment of active gastric and duodenal ulcers Adults: Administer 300 mg of nizatidine once daily at bedtime, or 150 mg twice daily, in the morning and evening, by mouth. Most ulcers heal within 4 weeks, but treatment may be continued for up to 8 weeks if necessary. Prevention of duodenal ulcer recurrence Adults: After healing of a duodenal ulcer, administer 150 mg orally once daily at bedtime. Treatment may be continued for up to 1 year; results of longer-term treatment are not known. Gastroesophageal reflux disease Adults: Administer 150 mg orally twice daily, in the morning and evening. Treatment may be continued for up to 12 weeks. Improvement of gastric mucosal lesions Adults: Administer 150 mg orally twice daily, in the morning and evening, for 2 weeks. Dosage adjustment for patients with severe renal impairment Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance 20–50 ml/min: 150 mg daily; < 20 ml/min: 150 mg every other day. Maintenance therapy: Creatinine clearance 20–50 ml/min: 150 mg every other day; < 20 ml/min: 150 mg every 3 days.

This medication should not be used in certain patients. First, it is not to be administered to patients with hypersensitivity to this drug or other H2-receptor antagonists. Also, this medication contains lactose, so it should not be used in patients with lactose intolerance or hereditary lactose degradation disorders. There are also patients for whom caution is needed when using this medication. Patients with a history of hypersensitivity to the drug, those with poor liver function, and patients with impaired kidney function should use this medication with caution. In particular, patients with decreased kidney function may have increased serum drug concentrations, therefore dosage should be reduced or dosing intervals increased. While using this medication, skin rash, itching, bronchial asthma, laryngeal edema, severe allergic reactions may rarely occur. If any of these symptoms occur, the use of the drug should be discontinued immediately. Blood-related abnormalities such as anemia, leukopenia, and thrombocytopenia have been reported, while gastrointestinal disturbances such as constipation, diarrhea, and nausea may occur. Liver function abnormalities may also arise, with elevated liver enzymes or symptoms of hepatitis and jaundice. Neurological symptoms may rarely include confusion, headache, drowsiness, dizziness, and rapid heartbeat. In women, gynecomastia may rarely occur, and in men, impotence or reduced libido has been reported. Skin-related abnormalities may include sweating, urticaria, rashes, and dermatitis, and other symptoms related to gout may include high uric acid levels, fever, and muscle pain. This medication can mask symptoms of gastric cancer, so it should only be used after confirming that it is not malignant. Since it is primarily excreted through the kidneys, dosage adjustment is required for patients with moderate to severe kidney function impairment. If there is no therapeutic effect or if adverse reactions occur, it is advisable to switch to another treatment immediately. Pregnant or breastfeeding women should only use this medication if the benefits of treatment are deemed to outweigh the risks, as its safety has not been fully established. Safety in children has not been established, and elderly patients should be carefully monitored for kidney function prior to administration due to the likelihood of kidney function decline. In case of overdose, symptoms such as vomiting, diarrhea, and miosis may occur, therefore immediate hospital treatment is required, and blood dialysis will not effectively remove the medication. This medication poses a low risk of interactions with other drugs; however, caution is required when used with high doses of aspirin as it may increase serum salicylate levels. When using this medication, it is important to take it exactly as directed by a physician and to consult a professional immediately if abnormal symptoms occur.

• Rash
• itching
• bronchial asthma
• laryngeal edema
• anaphylaxis symptoms
• anemia
• leukopenia
• neutrophilia
• thrombocytopenic purpura
• constipation

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It should also be protected from direct sunlight and stored at room temperature that is neither too hot nor too cold.

Appearance

[Domestic] Hard capsule with a yellow upper part and a pale yellow lower part containing a whitish powder [Export 1] Hard capsule with a yellow upper part and a pale yellow lower part containing a pale yellow content [Export 2] Hard capsule with a pale upper part and a pale yellow lower part containing a whitish powder

Package unit

[Domestic] 30 capsules/bottle, 300 capsules/bottle [Export 1, 2] 30 capsules/box (10 capsules/PTP*3)